Longevity & Biohacking · Connor Wells · 20 November 2026

James Peyer on turning aging biology into medicine

James Peyer on turning aging biology into medicine

James Peyer, co-founder and CEO of Cambrian Bio, frames james peyer turning aging into clinic-ready drugs around stepping-stone approvals: treat a real disease first, then expand. Cambrian’s AMPK activator ATX-304 drives fat loss without lean-mass loss in mice and raised resting metabolism in a small human study, with safer mTOR inhibitors next.

Key Takeaways

What is James Peyer’s strategy for turning aging biology into medicine?

In a Lifespan.io interview published November 20, 2026, Peyer traced about 25 years in longevity science—from early aging biology through Apollo Health Ventures to seven years running Cambrian Bio.

His core thesis is practical: a gerotherapeutic should first be approved for a concrete indication such as a rare disease, cancer, or metabolic condition, then expand toward prevention. That stepping-stone path, he said, is what sophisticated investors can fund today.

Efforts such as XPRIZE Healthspan and ARPA-H’s PROSPR focus on intrinsic capacity are valuable explorers, but he expects early wins from drugs already approved for something else. Follow related coverage in our Longevity & Biohacking hub.

How does Cambrian’s AMPK drug ATX-304 work?

AMPK has long been a pharma target because activating it extends lifespan in lower organisms and produces exercise-mimetic effects in animals, while human AMPK activation declines almost linearly with age.

Prior approaches fell short. Metformin activates AMPK via energy stress and can blunt exercise capacity. Direct activators from Merck and Pfizer increased sugar uptake without matching mitochondrial spend. Classic uncouplers such as dinitrophenol were dangerously toxic.

ATX-304, Peyer said, raises AMPK activity, glucose uptake, and mitochondrial respiration together so cells stay in homeostasis. In obese mice, monotherapy cut weight about as much as semaglutide—roughly 20% over a month—while animals ate the same or more, lost fat rather than lean mass, and more than doubled running endurance without training.

Paired with a GLP-1 in mice, weight fell nearly 30% in 15 days, forcing the lab to stop the combination. Peyer sees ATX-304 as an alternative, add-on, or oral maintenance option—not a GLP-1 replacement.

What have early human trials shown so far?

In a four-month exploratory trial with 23 patients, two doses showed safety and tolerability comparable to placebo. At about half the rodent and canine weight-loss exposure, resting metabolic rate rose about 8%, adiponectin roughly doubled, triglycerides fell, and liver and visceral fat declined—all statistically significant in that small study.

He likened the intended lift to roughly a daily three-mile run, kept within a youthful physiological AMPK range. Full mouse lifespan studies are still pending, though longer disease-model work in older mice and lifespan gains in flies and worms point the same direction, he said.

What else is in the pipeline, and how does related aging research fit?

Cambrian is also advancing mTOR complex 1-selective inhibitors that, in company data, can be dosed far above rapamycin’s immunosuppressive threshold without immune suppression. Those candidates are headed toward a disease indication and toward PROSPR-linked intrinsic-capacity trials in healthy elderly people.

Peyer still flags epigenetic partial reprogramming as promising when paired with a clear first indication, citing Life Biosciences’ optic-nerve program. That caution matches a Gladstone preprint finding that younger epigenetic ages and better function do not always travel together across human fibroblasts, T cells, and endothelial cells after transient OSKM exposure.

Separately, new mouse work links Granzyme K from aged CD8+ T cells to fibrosis and organ aging, another reminder that multi-pathway biology still has to become one approved medicine at a time.

← Open in blast feed